Factor VIII activation by factor VIIa analog (V158D/E296V/M298Q) in tissue factor-independent mechanisms^[*]

Summary

Factor (F)VIIa with tissue factor (TF) is a primary trigger of blood coagulation. The recombinant (r)FVIIa analog, NN1731 (V158D/E296V/ M298Q) containing a thrombin/FIXa-mimicking catalytic domain, is ~30-fold more effective on activated platelets without TF, but ~1.2-fold with TF, than rFVIIa for FX activation. We have recently demonstrated the FVIIa/TF-dependent FVIII activation in the early coagulation phase. We assessed the action of NN1731 on FVIII activation. NN1731/TF increased FVIII activity ~2.9-fold within 30 seconds, followed by rapid inactivation, and was slightly more active than rFVIIa/TF. NN1731-catalysed activation, however, was enhanced ~6-fold at 5 minutes (min), and its peak level persisted for ~30 min. NN1731/TF proteolysed FVIII at Arg⁷⁴⁰, Arg³⁷², and Arg³³⁶, similar to rFVIIa/TF, but cleavage by NN1731 alone was much slower at Arg³³⁶ than at Arg⁷⁴⁰ and Arg³⁷². The K_m and V_max for NN1731/TF-catalysed activation were ~1.8-fold lower and ~2.3-fold greater than rFVIIa/TF. The K_m for NN1731 alone was ~1.3-fold lower than rFVIIa, whilst the V_max was ~7.9-fold greater, indicating that the efficiency of FVIII activation by NN1731 and NN1731/TF was ~11- and ~4-fold greater, respectively, than equivalent reactions with rFVIIa. In SPR-based assays, NN1731 bound to FVIII and the heavy chain (K_d; 0.62 and 1.9 nM) with ~1.4- and ~3.1-fold higher affinity than rFVIIa, and the A2 domain contributed to this increase. Von Willebrand factor moderated NN1731-catalysed activation more significantly than NN1731/TF. In conclusion, NN1731 was a greater potential than rFVIIa in up-regulating FVIII activity, and the TF-independent FVIII activation might represent a potential extra mode of its enhanced haemostatic effect.

Keywords

Factor VIII(a) - factor VIIa-analog - activation - cleavage - tissue factor

Notes

^* An account of this work was presented at the 50th annual meeting of the American Society of Hematology, December 7, 2008, San Francisco, CA, USA.

• References

• 1 Mann KG, Nesheim ME, Church WR. et al. Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 1990; 76: 1-16.
• 2 Wood WI, Capon DJ, Simonsen CC. et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-337.
• 3 Eaton D, Rodriguez H, Vehar GA. Proteolytic processing of human factor VIII. Correlation of specific cleavages by thrombin, factor Xa, and activated protein C with activation and inactivation of factor VIII coagulant activity. Biochemistry 1986; 25: 505-512.
• 4 Fay PJ. Activation of factor VIII and mechanisms of cofactor action. Blood Rev 2004; 18: 1-15.
• 5 Fay PJ, Mastri M, Koszelak ME. et al. Cleavage of factor VIII heavy chain is required for the functional interaction of A2 subunit with factor IXa. J Biol Chem 2001; 276: 12434-12439.
• 6 Lollar P, Hill-Eubanks DC, Parker CG. Association of the factor VIII light chain with von Willebrand factor. J Biol Chem 1988; 263: 10451-10455.
• 7 Nogami K, Wakabayashi H, Schmidt K. et al. Altered interactions between the A1 and A2 subunits of factor VIIIa following cleavage of A1 subunit by factor Xa. J Biol Chem 2003; 278: 1634-1641.
• 8 Komiyama Y, Pedersen AH, Kisiel W. Proteolytic activation of human factors IX and X by recombinant human factor VIIa: effects of calcium, phospholipids, and tissue factor. Biochemistry 1990; 29: 9418-9425.
• 9 Hoffman M. Remodeling the blood coagulation cascade. J Thromb Thrombolysis 2003; 16: 17-20.
• 10 Mann KG, Krishnaswamy S, Lawson JH. Surface-dependent hemostasis. Semin Hematol 1992; 29: 213-226.
• 11 Soeda T, Nogami K, Matsumoto T. et al. Mechanisms of factor VIIa-catalyzed activation of factor VIII. J Thromb Haemost 2010; 8: 2494-2503.
• 12 Newell JL, Fay PJ. Cleavage at Arg1689 influences heavy chain cleavages during thrombin-catalyzed activation of factor VIII. J Biol Chem 2009; 284: 11080-11089.
• 13 Gabriel DA, Li X, Monroe 3^rd DM. et al. Recombinant human factor VIIa (rFVIIa)can activate factor FIX on activated platelets. J Thromb Haemost 2004; 2: 1816-1822.
• 14 Hedner U. Mechanism of action, development and clinical experience of recombinant FVIIa. J Biotechnol 2006; 124: 747-757.
• 15 Monroe D, Hoffman M, Oliver J. et al. Platelet activity of high-dose factor VIIa in independent of tissue factor. Br J Haematol 1997; 99: 542-547.
• 16 Brophy DF, Martin EJ, Nolte ME. et al. Effect of recombinant factor VIIa variant (NN1731) on platelet function, clot structure and force onset time in whole blood from healthy volunteers and haemophilia patients. Haemophilia 2007; 13: 533-541.
• 17 Persson E, Kjalke M, Olsen OH. Rational design of coagulation factor VIIa variants with substantially increased intrinsic activity. Proc Natl Acad Sci USA 2001; 98: 13583-13588.
• 18 Allen GA, Persson E, Campbell A. et al. A variant of recombinant factor VIIa with enhanced procoagulant and antifibrinolytic activities in an in vitro model of hemophilia. Arterioscler Thromb Vasc Biol 2007; 27: 683-689.
• 19 Holmberg HL, Lauritzen B, Tranholm M. et al. Faster onset of effect and greater efficacy of NN1731 compared with rFVIIa, aPCC and FVIII in tail bleeding in hemophilic mice. J Thromb Haemost 2009; 7: 1517-1522.
• 20 Sorensen B, Persson E, Ingerslev J. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A. Br J Haematol 2007; 137: 158-165.
• 21 Nogami K, Nishiya K, Saenko EL. et al. Identification of a plasmin-interactive site within the A2 domain of the factor VIII heavy chain. Biochim Biophys Acta 2008; 1784: 753-763.
• 22 Pipe SW, Kaufman RJ. Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa. Proc Natl Acad Sci USA 1997; 94: 11851-11856.
• 23 Takeshima K, Smith C, Tait J. et al. The preparation and phospholipid binding property of the C2 domain of human factor VIII. Thromb Haemost 2003; 89: 88-94.
• 24 Shima M, Scandella D, Yoshioka A. et al. A factor VIII neutralizing monoclonal antibody and a human inhibitor alloantibody recognizing epitopes in the C2 domain inhibit factor VIII binding to von Willebrand factor and to phosphatidylserine. Thromb Haemost 1993; 69: 240-246.
• 25 Foster PA, Fulcher CA, Houghten RA. et al. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain. J Clin Invest 1998; 82: 123-128.
• 26 Mimms LT, Zampighi G, Nozaki Y. et al. Phospholipid vesicle formation and transmembrane protein incorporation using octyl glucoside. Biochemistry 1981; 20: 833-840.
• 27 Warren DL, Morrissey JH, Neuenschwander PF. Proteolysis of blood coagulation factor VIII by the factor VIIa-tissue factor complex: generation of an inactive factor VIII cofactor. Biochemistry 1999; 38: 6529-6536.
• 28 Sorensen BB, Persson E, Freskgârd PO. et al. Incorporation of an active site inhibitor in factor VIIa alters the affinity for tissue factor. J Biol Chem 1997; 272: 11863-11868.
• 29 Jesty J, Wun TC, Lorenz A. Kinetics of the inhibition of factor Xa and the tissue factor-factor VIIa complex by the tissue factor pathway inhibitor in the presence and absence of heparin. Biochemistry 1994; 33: 12686-12694.
• 30 qvan 't Veer C, Hackeng TM, Delahaye C. et al. Activated factor X and thrombin formation triggered by tissue factor on endothelial cell matrix in a flow model: effect of the tissue factor pathway inhibitor. Blood 1994; 84: 1132-1142.
• 31 Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009; 15: 3-10.
• 32 Kasuda S, Tanaka I, Shima M. et al. Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors. Haemophilia 2004; 10: 341-346.
• 33 Meeks SL, Healey JF, Parker ET. et al. Anti-human factor VIII C2 domain antibodies in hemophilia A mice recognize a functionally complex continuous spectrum of epitopes dominated by inhibitors of factor VIII activation. Blood 2007; 110: 4234-4242.
• 34 Yada K, Nogami K, Ogiwara K. et al. Effects of anti-factor VIII inhibitor antibodies on factor VIIa/tissue factor-catalyzed activation and inactivation of factor VIII. Thromb Haemost 2011; 106: 989-998.